Display options
Cite
Adkinson NF, Strauss WE, Bernard K, et al. Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions. J Blood Med. 2017;8:155-163doi: 10.2147/JBM.S142236.
Adkinson, N. F., Strauss, W. E., Bernard, K., Kaper, R. F., Macdougall, I. C., & Krop, J. S. (2017). Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions. Journal of blood medicine, 8155-163. https://doi.org/10.2147/JBM.S142236
Adkinson, N Franklin, et al. "Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions." Journal of blood medicine vol. 8 (2017): 155-163. doi: https://doi.org/10.2147/JBM.S142236
Adkinson NF, Strauss WE, Bernard K, Kaper RF, Macdougall IC, Krop JS. Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions. J Blood Med. 2017 Sep 26;8:155-163. doi: 10.2147/JBM.S142236. eCollection 2017. PMID: 29033620; PMCID: PMC5628663.
Copy Download .nbib Format: NLM
Share it on

J Blood Med. 2017 Sep 26;8:155-163. doi: 10.2147/JBM.S142236. eCollection 2017.

Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions.

Journal of blood medicine

N Franklin Adkinson, William E Strauss, Kristine Bernard, Robert F Kaper, Iain C Macdougall, Julie S Krop

Affiliations

  1. Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  2. AMAG Pharmaceuticals, Inc., Waltham, MA, USA.
  3. Department of Renal Medicine, King's College Hospital, London, UK.

PMID: 29033620 PMCID: PMC5628663 DOI: 10.2147/JBM.S142236

Abstract

BACKGROUND: Intravenous (IV) iron is often used to treat iron deficiency anemia in patients who are unable to tolerate or are inadequately managed with oral iron. However, IV iron treatment has been associated with acute hypersensitivity reactions. The comparative risk of adverse events (AEs) with IV iron preparations has been assessed by a few randomized controlled trials, which are most often limited by small patient numbers, which lack statistical power to identify differences in low-frequency AE such as hypersensitivity reactions.

MATERIALS AND METHODS: Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (FIRM) is a randomized, double-blind, international, multicenter, Phase III study designed to compare the safety of ferumoxytol and ferric carboxymaltose (FCM). The study includes adults with hemoglobin <12.0 g/dL (females) or <14.0 g/dL (males), transferrin saturation ≤20% or ferritin ≤100 ng/mL within 60 days of dosing, and a history of unsatisfactory or nontolerated oral iron therapy or in whom oral iron therapy is inappropriate. Patients are randomized (1:1) to ferumoxytol 510 mg or FCM 750 mg, each given intravenously on days 1 and 8. Primary end points are the incidence of moderate-to-severe hypersensitivity reactions, including anaphylaxis, and moderate-to-severe hypotension. All potential hypersensitivity and hypotensive reactions will be adjudicated by a blinded, independent Clinical Events Committee. A secondary safety end point is the composite frequency of moderate-to-severe hypersensitivity reactions, including anaphylaxis, serious cardiovascular events, and death. Secondary efficacy end points include mean change in hemoglobin and mean change in hemoglobin per milligram of iron administered from baseline to week 5. Urinary excretion of phosphorus and the occurrence of hypophosphatemia after IV iron administration will be examined as well as the mechanisms of such hypophosphatemia in a substudy.

CONCLUSION: FIRM will provide data on the comparative safety of ferumoxytol and FCM, two IV iron preparations with similar dosing schedules, focusing on moderate-to-severe hypersensitivity reactions, including anaphylaxis, and moderate-to-severe hypotension. The study plans to enroll 2000 patients and is expected to complete in 2017.

Keywords: anaphylaxis; ferric carboxymaltose; ferumoxytol; hypersensitivity; hypotension; iron deficiency anemia

Conflict of interest statement

Disclosure NFA is a paid consultant for AMAG Pharmaceuticals, Inc. WES, KB, RK, and JK are employees of AMAG Pharmaceuticals, Inc. ICM has received speakers fees, honoraria, and consultancy fees from

References

  1. Ren Fail. 2007;29(4):423-6 - PubMed
  2. Clin Exp Gastroenterol. 2016 Jul 11;9:151-62 - PubMed
  3. Neth J Med. 2014 Jan;72(1):49-53 - PubMed
  4. J Bone Miner Res. 2013 Aug;28(8):1793-803 - PubMed
  5. Ren Fail. 2008;30(6):629-38 - PubMed
  6. Bone. 1997 Jul;21(1):57-64 - PubMed
  7. Transplantation. 2010 Oct 15;90(7):804-5 - PubMed
  8. BMJ Case Rep. 2017 Mar 13;2017: - PubMed
  9. PLoS One. 2017 Jan 30;12 (1):e0171098 - PubMed
  10. JAMA. 2015 Nov 17;314(19):2062-8 - PubMed
  11. J Allergy Clin Immunol. 2005 Mar;115(3 Suppl 2):S483-523 - PubMed
  12. Nephrol Dial Transplant. 2001 Jun;16(6):1239-44 - PubMed
  13. Nephron Clin Pract. 2005;99(4):c97-101 - PubMed
  14. Toxicology. 2005 Dec 15;216(2-3):106-21 - PubMed
  15. Kidney Int. 2016 Jan;89(1):28-39 - PubMed
  16. J Allergy Clin Immunol. 2006 Feb;117(2):391-7 - PubMed
  17. PLoS One. 2016 Dec 1;11(12 ):e0167146 - PubMed
  18. Transfusion. 2014 Feb;54(2):306-15 - PubMed
  19. J Clin Endocrinol Metab. 2009 Jul;94(7):2332-7 - PubMed
  20. Immunol Allergy Clin North Am. 2014 Aug;34(3):707-23, x-xi - PubMed
  21. Nephrol Dial Transplant. 2015 Dec;30(12 ):2068-75 - PubMed
  22. Am J Nephrol. 2017;45(1):60-62 - PubMed
  23. Ann Allergy Asthma Immunol. 2015 Nov;115(5):341-84 - PubMed
  24. Am J Hematol. 2014 Jun;89(6):646-50 - PubMed
  25. Endocr J. 1998 Aug;45(4):431-9 - PubMed
  26. Am J Nephrol. 2017;45(1):49-59 - PubMed
  27. Transfusion. 2009 Dec;49(12):2719-28 - PubMed
  28. Cold Spring Harb Perspect Med. 2013 Jul 01;3(7):null - PubMed
  29. J Allergy Clin Immunol. 2004 May;113(5):832-6 - PubMed
  30. Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12 - PubMed
  31. Ann Clin Biochem. 2009 Mar;46(Pt 2):167-9 - PubMed

Publication Types